製品番号: HY-N7926

Pentadecane

カスタマーレビュー

Based on 1 Customer Validation

Pentadecane is an orally active natural plant volatile alkane with anti-inflammatory, analgesic, antipyretic and anti-leishmanial activities. Pentadecane presents IC₅₀ values of 65.3 μM, 60.5 μM and 194.8 μM against Leishmania infantum promastigotes, amastigotes and intracellular amastigotes, respectively. Pentadecane downregulates the mRNA expression of TNF-α and IL-12 and inhibits the release of inflammatory mediators. Pentadecane arrests the cell cycle of Leishmania infantum and induces apoptosis. Pentadecane can be applied to the research of inflammation and leishmaniasis.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 98.88%
CAS 番号: 629-62-9
分子式: C₁₅H₃₂
分子量:212.41

保管条件:

Store at room temperature 3 years.

In solvent -80°C, 2 years , -20°C, 1 year

Pentadecane 構造式

CAS 番号: 629-62-9

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
- 体内実験
化学情報
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target^[1]^[3]

IL-12

TNF-α

Leishmania

TNF Receptor アイソフォーム固有の製品をすべて表示 :

Parasite アイソフォーム固有の製品をすべて表示 :

Interleukin Related アイソフォーム固有の製品をすべて表示 :

体外実験

Pentadecane (10-60 µg/mL; overnight) does not inhibit the growth of Staphylococcus aureus, Bacillus subtilis, Escherichia coli, or Pseudomonas aeruginosa^[1].
Pentadecane (60 µg/mL; 8 h) temporarily inhibits the growth of Staphylococcus aureus, Bacillus subtilis, Escherichia coli, and Pseudomonas aeruginosa over an 8-hour period, but does not prevent long-term bacterial growth^[1].
Pentadecane (10-70 µg/mL; 48 h pre-incubation, followed by 48 h LPS/IFN-γ stimulation) significantly downregulates TNF-α and IL-12 mRNA expression in LPS/IFN-γ-induced M1 phenotype U937 macrophages, with the most potent TNF-α inhibition seen at 10 µg/mL in hexane^[1].
Pentadecane (50-300 μM; 48 h) inhibits the viability of Leishmania infantum promastigotes (IC₅₀ = 65.3 μM) and axenic amastigotes (IC₅₀ = 60.5 μM) in a dose-dependent manner^[3].
Pentadecane (65.3-300 μM; 48 h) induces apoptotic-like morphological changes (loss of cell volume, nuclear condensation) in Leishmania infantum promastigotes^[3].
Pentadecane (65.3 μM; 24 h) induces cell cycle arrest in Leishmania infantum promastigotes, increasing the proportion of cells in the sub-G0/G1 phase and eliminating cells in the G2/M phase^[3].
Pentadecane (50-300 μM; 48 h) causes negligible cytotoxicity in DH82 dog macrophage cells, U937 human histiocytic lymphoma cells, and normal CPE primary epithelial cells^[3].
Pentadecane (300 μM; 48 h) inhibits the growth of Leishmania infantum intracellular amastigotes in U937-derived macrophages, reducing infection by 77% at 300 μM and exhibiting an IC₅₀ of 194.8 μM^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Real Time qPCR^[1]

Cell Line:

LPS/IFN-γ-induced M1 phenotype U937 human monocytic macrophages
Concentration:

10, 70 µg/mL
Incubation Time:

48 h pre-incubation, followed by 48 h LPS/IFN-γ stimulation
Result:

Showed the most significant downregulation of TNF-α mRNA expression at 10 µg/mL (hexane) compared to the LPS-treated M1 control.
Significantly downregulated IL-12 mRNA expression at all tested concentrations compared to the LPS-treated M1 control.
Showed no significant difference in IL-12 mRNA expression from the 10% hexane control group at 70 µg/mL (hexane).

Cell Viability Assay^[1]

Cell Line:

human dermal fibroblast (HDF) cells
Concentration:

10, 20, 30, 40, 50, 60, 70 µg/mL
Incubation Time:

48 h
Result:

Resulted in average cell viability between 58% and 103%, with viability averagely higher than cells treated with palmitic acid.

Cell Viability Assay^[3]

Cell Line:

DH82 dog macrophage cells, U937 human histiocytic lymphoma cells, primary epidermal cells of CPE
Concentration:

50 μM, 100 μM, 150 μM, 200 μM, 250 μM, 300 μM
Incubation Time:

48 h
Result:

Maintained DH82 cell viability between ~78% and ~94%.
Maintained CPE cell viability between ~84% and ~122%.
Maintained U937 cell viability between ~86% and ~137%.
Resulted in all tested cell lines showing viability higher than 60% across all concentrations, indicating negligible cytotoxicity.

体内実験

Pentadecane (1000 mg/kg; p.o.; daily; 14 days) shows no apparent acute toxicity in Sprague-Dawley rats at an oral dose of 1000 mg/kg daily for 14 days^[2].
Pentadecane (5, 10 mg/kg; p.o.; single dose) exhibits significant dose-dependent analgesic activity in the acetic acid-induced writhing model in Sprague-Dawley rats^[2].
Pentadecane (5, 10 mg/kg; p.o.; single dose) exhibits significant analgesic activity targeting inflammatory nociception in the formalin-induced paw licking model in Sprague-Dawley rats^[2].
Pentadecane (5, 10 mg/kg; p.o.; single dose) exhibits significant anti-inflammatory activity in the carrageenan-induced paw edema model in Sprague-Dawley rats^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

化学情報

CAS 番号 629-62-9
性状 Liquid (Density: 0.769 g/cm³)
分子量 212.41
分子式 C₁₅H₃₂
Color Colorless to off-white
SMILES

CCCCCCCCCCCCCCC
Structure Classification
- Others
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Store at room temperature 3 years

In solvent	-80°C	2 years
	-20°C	1 year

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (470.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.7079 mL

23.5394 mL

47.0788 mL

5 mM

0.9416 mL

4.7079 mL

9.4158 mL

10 mM

0.4708 mL

2.3539 mL

4.7079 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (11.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (11.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (11.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (273 KB)
SDS (623 KB)
- English - EN (623 KB)
- Français - FR (623 KB)
- Deutsch - DE (623 KB)
- Norwegian - NO (623 KB)
- Español - ES (623 KB)
- Swedish - SV (623 KB)
- Italian - IT (623 KB)
- Korean - KR (623 KB)
- Portuguese - PT (623 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Chuah XQ. Eicosane, pentadecane and palmitic acid: The effects in in vitro wound healing studies. Asian Pac J Trop Biomed. 2018 Oct;8(10):490-499.

[2]. Patrick Nwabueze Okechukwu. Evaluation of anti-inflammatory, analgesic, antipyretic effect of eicosane, pentadecane, octacosane, and heneicosane. Asian Journal of Pharmaceutical and Clinical Research. 2020 May;13(4).

[3]. Bruno F, et al. Cytotoxic Screening and In Vitro Evaluation of Pentadecane Against Leishmania infantum Promastigotes and Amastigotes. J Parasitol. 2015;101(6):701-705. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.7079 mL	23.5394 mL	47.0788 mL	117.6969 mL
	5 mM	0.9416 mL	4.7079 mL	9.4158 mL	23.5394 mL
	10 mM	0.4708 mL	2.3539 mL	4.7079 mL	11.7697 mL
	15 mM	0.3139 mL	1.5693 mL	3.1386 mL	7.8465 mL
	20 mM	0.2354 mL	1.1770 mL	2.3539 mL	5.8848 mL
	25 mM	0.1883 mL	0.9416 mL	1.8832 mL	4.7079 mL
	30 mM	0.1569 mL	0.7846 mL	1.5693 mL	3.9232 mL
	40 mM	0.1177 mL	0.5885 mL	1.1770 mL	2.9424 mL
	50 mM	0.0942 mL	0.4708 mL	0.9416 mL	2.3539 mL
	60 mM	0.0785 mL	0.3923 mL	0.7846 mL	1.9616 mL
	80 mM	0.0588 mL	0.2942 mL	0.5885 mL	1.4712 mL
	100 mM	0.0471 mL	0.2354 mL	0.4708 mL	1.1770 mL

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Pentadecane

Differentiation Inducing Compound Library

Lipid Compound Library

Medicine Food Homology Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Blood Cancer Compound Library

Antiparasitic Compound library

Angiogenesis-Related Compound Library

Food-Sourced Compound Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Flavor Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Chinese Baijiu Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Natural Product and Natural Product-Like Compound Library

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Natural Product Library

TNF Receptor アイソフォーム固有の製品をすべて表示

Parasite アイソフォーム固有の製品をすべて表示

Interleukin Related アイソフォーム固有の製品をすべて表示

生物活性

化学情報

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Pentadecane 関連分類

HY-N7926 関連分類